Research Analysts Offer Predictions for PepGen Inc.’s Q2 2022 Earnings (NASDAQ:PEPG)

PepGen Inc. (NASDAQ:PEPGGet Rating) – Analysts at Wedbush issued their Q2 2022 EPS estimates for PepGen in a research report issued to clients and investors on Tuesday, May 31st. Wedbush analyst L. Chico anticipates that the company will post earnings per share of ($0.88) for the quarter. Wedbush has a “Outperform” rating and a $17.00 price objective on the stock. Wedbush also issued estimates for PepGen’s Q3 2022 earnings at ($0.62) EPS, Q4 2022 earnings at ($0.65) EPS, FY2022 earnings at ($3.50) EPS, Q1 2023 earnings at ($0.67) EPS, Q2 2023 earnings at ($0.70) EPS, Q3 2023 earnings at ($0.73) EPS, Q4 2023 earnings at ($0.75) EPS, FY2023 earnings at ($2.85) EPS, FY2024 earnings at ($3.26) EPS, FY2025 earnings at ($3.67) EPS and FY2026 earnings at ($4.64) EPS.

A number of other equities analysts also recently weighed in on the stock. SVB Leerink began coverage on shares of PepGen in a report on Tuesday. They set an “outperform” rating and a $40.00 target price on the stock. Stifel Nicolaus assumed coverage on shares of PepGen in a report on Tuesday. They set a “buy” rating and a $24.00 target price on the stock. Finally, Bank of America initiated coverage on shares of PepGen in a research report on Tuesday. They set a “buy” rating and a $16.00 price objective for the company.

NASDAQ PEPG opened at $10.92 on Thursday. PepGen has a 1-year low of $7.82 and a 1-year high of $16.99.

PepGen Company Profile (Get Rating)

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen Inc is based in BOSTON.

Featured Stories

Earnings History and Estimates for PepGen (NASDAQ:PEPG)

Want More Great Investing Ideas?

Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.